A review of studies evaluating medical cannabis for the chronic pain management
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.024Keywords
Cannabis, endocannabinoids, Δ9-tetrahydrocannabinol, cannabidiol, chronic painAbstract
Introduction: Medical cannabis for patients with chronic pain related to various conditions has been the focus of numerous investigations. Cannabis-based medicine has been described for hundreds of years but only recently have we seen the more scientific, evidence-based approach to its use, and ongoing investigations continue to explore its potential medical benefits.
State of knowledge: As the results of studies assessing medical cannabis in pain alleviate seem promising, only weak recommendations are available. Important factors to consider in the development of guidelines include optimal doses, routes of administration and used types of cannabinoids. In discussed studies no serious adverse events were reported and treatment was well tolerated by participants.
Conclusions: Evidence suggests that cannabis-based medicine can be safe and effective in pain relief. Further high-quality randomised clinical trial studies are needed. It is important to assess the safety profile of each individual cannabinoid formulation and define the population that can benefit from cannabis therapy for establishment of prospective recommendations and guidelines.
References
Zuardi AW. History of cannabis as a medicine: a review. Braz J Psychiatry. 2006;28(2):153-157
Owens B. Drug development: The treasure chest. Nature. 2015;525(7570):S6-S8
Lee G, Grovey B, Furnish T, Wallace M. Medical Cannabis for Neuropathic Pain. Curr Pain Headache Rep. 2018;22(1):8
Zieglgänsberger W, Brenneisen R, Berthele A, et al. Chronic Pain and the Endocannabinoid System: Smart Lipids - A Novel Therapeutic Option?. Med Cannabis Cannabinoids. 2022;5(1):61-75
Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20(Suppl 1):10–14
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, et al. Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. EFSA J. 2022;20(6):e07322
Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. 2021;374:n2040
Maharajan MK, Yong YJ, Yip HY, et al. Medical cannabis for chronic pain: can it make a difference in pain management?. J Anesth. 2020;34(1):95-103
Schwan J, Sclafani J, Tawfik VL. Chronic Pain Management in the Elderly. Anesthesiol Clin. 2019;37(3):547-560
van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860-869
Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020;24(8):1505-1516
Nielsen S, Picco L, Murnion B, et al. Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. Neuropsychopharmacology. 2022;47(7):1315-1330
Zylla DM, Eklund J, Gilmore G, et al. A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer. 2021;29(12):7471-7478
Abrams DI, Couey P, Dixit N, et al. Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(7):e2010874
de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H; Pain and Nociception Neuroscience Research Group. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. Clin Gastroenterol Hepatol. 2017;15(7):1079-1086.e4
Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol. 2019;37 Suppl 116(1):13-20
Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021;214(8):370-375
Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2020;21(5):390-402
Baratta F, Pignata I, Ravetto Enri L, Brusa P. Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation. Front Pharmacol. 2022;13:888903
Macedo AC, de Faria AOV, Bizzi I, Moreira FA, Colasanti A, Ghezzi P. Online information on medical cannabis is not always aligned with scientific evidence and may raise unrealistic expectations. J Cannabis Res. 2022;4(1):37
Gottschling S, Ayonrinde O, Bhaskar A, et al. Safety Considerations in Cannabinoid-Based Medicine. Int J Gen Med. 2020;13:1317-1333
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Justyna Żyga
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 685
Number of citations: 0